

Revision of consolidated earnings forecasts for FY 2013

In light of expected effects from the planned unification from fiscal 2013 of the accounting period for Santen group companies in line with the planned voluntary adoption from fiscal 2014 of the International Financial Reporting Standards (IFRS) and an expected increase in revenue from the pharmaceutical business, Santen Pharmaceutical Co., Ltd. has revised consolidated financial forecasts for fiscal 2013, ending in March 2014, released on November 6, 2013.

Revision of consolidated financial forecasts for FY 2013

(covering period between April 1, 2013 and March 31, 2014)

After reflecting unification of accounting period*

(unit: ¥ million)	Net Sales	Operating Profit	Ordinary Income	Net Profit	Net Income Per Share
Previous forecasts (A) (released on Nov. 6, 2013)	141,500	26,300	26,800	18,200	JPY 215.72
Revised forecasts (B) (After reflecting unification of accounting period)	149,000	26,500	27,500	17,500	JPY 207.43
Change (B-A)	7,500	200	700	△700	JPY △8.29
Percentage change	5.3%	0.8%	2.6%	△3.8%	

(Reference: Before reflecting unification of accounting period *)

(unit: ¥ million)	Net Sales	Operating Profit	Ordinary Income	Net Profit	Net Income Per Share
Previous forecasts (A) (released on Nov. 6, 2013)	141,500	26,300	26,800	18,200	JPY 215.72
Revised forecasts (B) (Before reflecting unification of accounting period)	146,000	27,500	28,500	18,500	JPY 219.28
Change (B-A)	4,500	1,200	1,700	300	JPY 3.56
Percentage change	3.2%	4.6%	6.3%	1.6%	
Results of FY 2012	119,066	24,681	25,602	16,520	JPY 195.81

* Santen Pharmaceutical Co., Ltd. decided to unify from fiscal 2013 of the accounting period for Santen group companies in line with the International Financial Reporting Standards (IFRS).